Physician
Nephrology
Dr. Suzanne K. Swan, MD
|
|
Give Review
Suzanne K. Swan, MD is an expert in the field of Nephrology. She researched medicine at Indiana University School of Medicine. Indiana University School of Medicine is ranked 45/47 in Research/PrimaryCare. She received 1 awards: "Fellow (FACP)". Suzanne Swan is a published doctor and has 75 publications published. The lastest was: 'The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function.'
Publications
- Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart Failure.
- Pharmacokinetics and safety of sunitinib malate in subjects with impaired Renal function.
- Effect of Renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.
- Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of Renal impairment.
- Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, rando...
- Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with Renal dysfunction.
- Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers.
- A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage Renal disease.
- The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients.
- Pharmacokinetics and safety of the ketolide telithromycin in patients with Renal impairment.
- Tegaserod pharmacokinetics are similar in patients with severe Renal insufficiency and in healthy subjects.
- Does uremia protect against the demyelination associated with correction of hyponatremia during hemodialysis? A case report and literature review.
- Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with Chronic renal dysfunction.
- Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing Chronic hemodi...
- Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
- Pharmacologic limits of the protective effect of polyaspartic acid on experimental gentamicin nephrotoxicity.
- Duration of the protective effect of polyaspartic acid on experimental gentamicin nephrotoxicity.
- Cyst decompression surgery for autosomal dominant polycystic Kidney disease.
- Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis.
- Effect of lovastatin on the development of polycystic Kidney disease in the Han:SPRD rat.
- Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart Failure.
- The angiotensin II receptor antagonist losartan reduces blood pressure but not Renal injury in obese Zucker rats.
- Review article: the pharmacokinetics of rabeprazole in health and Disease.
- Isoprenoids and Ras: potential role in Chronic rejection.
- Immunosuppressive effects of leflunomide in experimental Chronic vascular rejection.
- Aminoglycoside nephrotoxicity.
- Role of lipids in Chronic renal allograft rejection.
- Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects.
- Drug dosing guidelines in patients with renal Failure.
- Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study.
- "Clinical pharmacology studies in patients with Renal impairment: past experience and regulatory perspectives".
- On the probability that Kidneys are different in autosomal dominant polycystic disease.
- Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis.
- The generation of non-dextran intravenous iron: is iron dextran obsolete?
- Results of a randomized open-label crossover study of the bioequivalence of subcutaneous versus intramuscular administration of alefacept.
- Effect of hepatic or Renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
- Diuretic strategies in patients with renal Failure.
- Predictive performance of Renal function estimate equations in Renal allografts.
- Long-term effects of reduced Renal mass in humans.
- The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of Renal function.
- Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis.
- Pharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe Renal impairment and in elderly subjects.
- Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of Renal function.
- The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of Renal impairment.
- Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients.
- The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and Renal hemodynamics in normotensive subjects.
- Phase 1 dose-escalation study of CP-690 550 in stable Renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharm...
- Pharmacokinetics of telbivudine in subjects with various degrees of Renal impairment.
- Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage Renal disease requiring hemodialysis.
- A preliminary placebo-controlled crossover trial of fludrocortisone for Chronic fatigue syndrome.
- Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with Renal impairment.
- Effect of CP-690,550, an orally active janus kinase inhibitor, on Renal function in healthy adult volunteers.
- Determination of residual Renal function with iohexol clearance in hemodialysis patients.
- Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal Failure.
- Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjects.
- Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with Renal insufficiency.
- Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with Renal impairment.
- The pharmacokinetics of ziprasidone in subjects with normal and impaired Renal function.
- The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or Renal dysfunction.
- Garenoxacin pharmacokinetics in subjects with Renal impairment.
- Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with Renal impairment.
- Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of re...
- Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.
- Effect of cyclooxygenase-2 inhibition on Renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.
- Pharmacokinetics of ertapenem in patients with varying degrees of Renal insufficiency and in patients on hemodialysis.
- Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
- Disposition of recombinant human interleukin-10 in subjects with various degrees of Renal function.
- Pharmacokinetics of flutamide in patients with Renal insufficiency.
- Pharmacokinetics of etoricoxib in patients with Renal impairment.
- Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of Chronic renal disease.
- Pharmacokinetics of pilocarpine in subjects with varying degrees of Renal function.
- Effect of impaired Renal function and haemodialysis on the pharmacokinetics of aprepitant.
- Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with Renal insufficiency.
- Pharmacokinetics and safety of ebastine in healthy subjects and patients with Renal impairment.
Schools
Northeastern Ohio Universities College Of Medicine
Tx Tech UHlth Science Center
Nrtheast Oh University College MedAffli Hospital
In University Med Center
Or Health Scie University
Procedures Preformed
- Hemodialysis
Conditions Treated
- Acidosis
- Acute Kidney Failure
- Alkalosis
- Amyloidosis
- View All
Doctors Specialties
- Nephrology
Accepted Insurances
Awards
- Fellow (FACP)
Education
-
Indiana University School of Medicine -
Oregon Health & Science University -
Texas Tech University at Lubbock -
Northeast Ohio Medical University
Helpful Reviews
Similar Doctors
|
|
Dr. Areef Ishani, MD |
|
|
Dr. Maria C. Rosales, MD |
|
|
Dr. Aleksandra K. Kukla, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wei Y. Kong, MD |
|
|
Dr. Charles L. Smith, MD |
|
|
Dr. Sunil Akkina, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George T. O'Bryan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward Muter, MD |